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Commonly conceptualized as neurodevelopmental disorders of yet poorly understood aetiology, schizophrenia and other
nonorganic psychoses remain one of the most debilitating illnesses with often poor outcome despite all progress in treatment
of the manifest disorder. Drawing on the frequent poor outcome of psychosis and its association with the frequently extended
periods of untreated first-episode psychosis (FEP) including its prodrome, an early detection and treatment of both the FEP and
the preceding at-risk mental state (ARMS) have been increasingly studied. Thereby both approaches are confronted with different
problems, for example, treatment engagement in FEP and predictive accuracy in ARMS.They share, however, the problems related
to the lack of understanding of developmental, that is, age-related, peculiarities and of the presentation and natural course of
their cardinal symptoms in the community. Most research on early detection and intervention in FEP and ARMS is still related to
clinical psychiatric samples, and little is known about symptompresentation and burden and help-seeking in the general population
related to these experiences. Furthermore, in particular in the early detection of an ARMS, studies often address adolescents and
young adults alike without consideration of developmental characteristics, thereby applying risk criteria that have been developed
predominately in adults. Combining our earlier experiences described in this paper in child and adolescent, and general psychiatry
as well as in both lines of research, that is, on early psychosis and its treatment and on the early detection of psychosis, in particular in
its very early states by subjective disturbances in terms of basic symptoms, age-related developmental and epidemiological aspects
have therefore been made the focus of our current studies in Bern, thus making our line of research unique.
1. Introduction
Schizophrenia and other nonorganic psychoses remain one of
the most debilitating illnesses [1, 2], despite all the progress
in treatment that has been made since the introduction of
antipsychotics in the 1960s.Though generally conceptualized
as a neurodevelopmental disorder, their aetiology is still
only poorly understood. Psychotic disorders have a life-time
prevalence of approximately 3.5% [3] and a 12-month inci-
dence rate of about 0.035% [4]. They usually first strike early
in life, between the ages of 20 and 25 [4, 5]; approximately 10–
15% are early-onset psychoses (EOP) manifesting themselves
before the age of 18, and approximately 1–3% are very-early-
onset psychoses (VEOP) with an onset before the age of 13
[6]. Despite their relatively low prevalence, psychoses are
one of the top-ten diseases with regard to disability-adjusted
life years (DALYs) [7–9]. Furthermore, the immense indirect
costs of these disorders, for example, caused by early and
lasting loss of productivity on the part of both patients and
their carers, make them one of the most costly disorders for
society [8, 9].
The high societal and personal cost are driven in part by
the poor course that psychoses tend to take after their initial
manifestation. A poor course however is, among others, a
consequence of the frequently long duration of unrecognized
and untreated psychosis (DUP) and illness, including the
prodrome (DUI) [10–13] even in persons seeking help early
[14, 15]. An extended prodrome of more than three years
precedes the majority of first-episode psychoses (FEP) [13,
16, 17]; however, the gradual progression characteristic of
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Figure 1: Hypothetical early course of psychosis in relation to primary and secondary preventive approaches (according to [164]).
Annotations: BS: basic symptoms; COPER: cognitive-perceptive basic symptoms; COGDIS: cognitive disturbances; APS: attenuated psychotic
symptoms; BLIPS: brief limited intermittent psychotic symptoms; DUP: duration of untreated psychosis; DUI: duration of untreated illness.
psychoses impedes the identification of a disorder by patients
and healthcare professionals. Thus, since the 1990s, efforts
have increasingly focused on detecting and treating FEP early,
preferably, in terms of indicated prevention, while the patient
is still within the prodromal state and before the onset of
persisting positive psychotic symptoms (Figure 1) [18–20].
As an example of these efforts, the present outlook
paper will summarize the research conducted by the two
authors, both being experts in this area of research, and their
perspectives on it and conclude with an outlook on future
questions that will have to be addressed.
2. The First Episode of Psychoses
2.1. The Melbourne Early Psychosis Prevention and Interven-
tion Centre (EPPIC). The Early Psychosis Prevention and
Intervention Centre (EPPIC) in Melbourne has been one of
the first programmes with a mandate to detect and treat all
patients with FEP of both early and young adult onset (mid-
teens to midtwenties) [21]. Gradually developing between
1984 and 1992, EPPIC services a sector with a population
of about 800,000 people. Working within a national mental
health system, it receives all referrals with suspicion of a
FEP. Thus, its database provides a unique and, in terms of
sampling, unbiased opportunity to analyse the characteristics
and treatment outcomes of all types of FEP [22–30] and
has a special focus on bipolar psychoses [23, 31, 32]. Such
detailed knowledge is important for identifying obstacles to
care and for detecting starting-points for early detection and
intervention in FEP and has therefore been in the special
focus of the work of Benno Schimmelmann.
2.1.1.The Early Course of First-Episode Psychosis. One impor-
tant finding of the EPPIC data was that diagnostic stability
over 18 months is high for first episodes of schizophrenic
psychoses with few shifts from schizophrenia to other diag-
noses. On the other hand, patients with a FEP diagnosis
of schizophreniform or bipolar disorder were diagnostically
unstable, with frequent shifts to other psychotic disorders,
mainly schizophrenia, necessitating longitudinal reassess-
ment of their diagnoses [33]. Thus, after their first episode,
most psychoses had a poor outcomewithin the first 18months
with the frequency of the diagnosis of its most severe type,
schizophrenia, increasing. Thereby, persistent substance use
over the treatment period but not baseline substance use was
associated with nonremission of psychotic symptoms after 18
months, even after controlling for many relevant predictors
of outcome [34]. Similarly, persistent cannabis use but not
cannabis use at baseline was a significant predictor of worse
outcome in early-onset psychosis [35]. Additionally cannabis
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use disorders starting before age 14 seem to predict an earlier
onset of psychosis [36]; an earlier onset, in turn, had been
associated with a poorer outcome [16]. Thus, substance and
in particular cannabis use seem to have differential and age-
related effects on the course of psychosis: accelerating the
onset of psychosis in young psychosis-prone adolescents and
corrupting the outcome of FEP in general, that is, across all
age groups.
2.1.2. Treatment Compliance in First-Episode Psychosis. Ad-
herence to treatment and medication is a significant problem
in early psychosis. In the FEP cohort of EPPIC (𝑁 =
661), 19% never took the prescribed medication and 23%
disengaged from the program despite significant efforts
to keep patients engaged in treatment (such as assertive
community treatment, specific crisis teams, and highly spe-
cialized case managers). Predictors of service disengagement
and medication nonadherence or refusal were persistent
substance use over the treatment period, a forensic his-
tory, and lack of family support [37, 38]. Those consis-
tently refusing all medications from the outset were more
likely to have a forensic history compared to those who
became nonadherent later on [38]. Service disengagement
was further predicted by moderate illness severity and a
lack of significant treatment success until disengagement
from both the entire sample and the adolescent subsample
[37, 39].
2.1.3. Early-Onset and Adult Onset Psychosis. With regard to
developmental peculiarities, the EPPIC cohort has provided
a unique opportunity to assess differences between EOP and
young adult onset psychosis (AOP; starting between ages
18 and 28). Due to EPPIC’s focus on a young age range,
about 19% of the sample was EOP patients (onset between
8.2 and 17.9 years). Compared to AOP patients, EOP had a
slightly lower premorbid functioning and considerably longer
duration of untreated psychosis (median 26.3 weeks in EOP
compared to 8.7 weeks in AOP). Notably, the significantly
longer DUP in EOP accounted for their worse course after
controlling for type of psychosis, level of premorbid function-
ing, family support, and psychiatric history. No significant
outcome differences including illness severity, global func-
tioning, remission of positive symptoms, or employment sta-
tus were detected between EOP and AOP [40, 41]. Hence the
negative effects of DUI and DUPmay be exacerbated in EOP.
The treatment delay observed in EOP may be due to several
factors, including themore pronounced neurodevelopmental
and cognitive deficits, the insidious onset of less pronounced
positive symptoms, and/or the atypical clinical picture of the
beginning EOP—potentially misinterpreted as “adolescent
crisis” [40]. Furthermore, as the age of onset of symptoms
seems to be earlier in adolescent cannabis users [42], early
symptoms might also be mistaken as substance-induced.
Thus, early detection and treatment of persons with the first
signs of the disorder, which is currently regarded as a promis-
ing strategy in fighting the consequences of psychosis, may
face different or additional challenges in EOP as compared to
AOP.
2.2. The Hamburg Psychosis Early Detection and Interven-
tion Project (PEDIC). Based on the EPPIC experience, the
Psychosis Early Detection and Intervention Project (PEDIC)
was implemented in Hamburg in 2003. One early research
focus of PEDIC was on remission and recovery of symptoms,
functioning, and subjective well-being in adults with FEP
[43–45].
2.2.1. Remission and Recovery in First-Episode Schizophrenia.
In a 3-year follow-up study of 392 never-treated patients
with schizophrenia cared for within PEDIC, remission rates
were 60% for symptoms, 45% for functional deficits, and 57%
for subjective well-being; corresponding recovery rates were
52%, 35%, and 44%; 28% were in combined remission and
17% in combined recovery (fulfilling all remission or recovery
criteria, resp.). Studies examining predictors of remission and
functional outcome have shown that premorbid and baseline
psychosocial functioning and good treatment response with
symptom remission within the first 3 months are the best
predictors of both [45–51]. These findings have important
clinical implications whereby the low proportion of patients
who met remission or recovery criteria clearly highlights the
importance of making adaptations to treatment early on [45].
Furthermore, our studies suggested that measures of quality
of life and subjective well-being should be assessed when
measuring the outcome of psychotic disorders [52–54]. The
patient’s perspective and experience might be particularly
important when it comes to assessment of the side effects of
antipsychotics. Because objective and subjective side effects
often differ and subjective impairment may be a stronger
predictor of nonadherence than objective measures of the
severity of side effects, assessing both objective and subjective
side effects has been strongly recommended [54].
2.2.2. Assertive Community Treatment in Schizophrenia-
Spectrum Disorders: The Access Trial. Despite all of the
knowledge gained about moderators of outcome in FEP, a
crucial, yet unresolved, question is how patients with psy-
chotic disorders are optimally treated. In Hamburg, we con-
structed a comprehensive treatment model for patients with
both first- and multiple-episode schizophrenia-spectrum
disorders, the ACCESS model, which included assertive
community treatment, specialized personnel, integration of
specific treatment options for psychotic patients such as
cognitive-behavioural psychotherapy, metacognitive train-
ing, and a general psychotherapeutic approach including
techniques of open dialogue [55–57]. At 12 months, patients
treated in the ACCESS program had better outcomes than
those treated as usual in an integrated care setting without
assertive community treatment, case management, or spe-
cialized personnel in terms of service engagement, symp-
toms, functioning, quality of life, and satisfaction with care.
The additional treatment effect of the ACCESS program was
clearly significant, and the costs of ACCESS were similar
to treatment as usual; therefore inpatient days were signif-
icantly decreased while outpatient contacts were increased
[58, 59]. ACCESS was then translated into clinical practice
and extended to bipolar psychotic disorders. The benefits of
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the ACCESS treatment model, particularly in terms of high
service engagement and low hospitalization rates, remained
stable over a 2-year period [60], yet their longer-term effects
remain to be studied.
2.3. GettingThere Even Earlier: Lessons fromFirst-Episode Psy-
chosis Research. Despite a broad range of efforts to improve
the outcome of FEP but also of multiepisode psychosis, many
patients continue to suffer from symptoms as well as poor
functioning and quality of life. Thus, not only is the early
identification of patients with manifest psychotic disorders
important in order to reduce the DUP [41], but also the early
detection of at-risk mental states (ARMS) is mandatory for
the reduction of DUI and the burden of psychotic disorders
in both adults [61] and children and adolescents [62–65].
3. The At-Risk Mental State
Since Kraepelin’s description of dementia praecox more than
a century ago [66], diagnosis, treatment, and studies of
psychosis have focused mainly on its cardinal positive and
negative symptoms. In the last two decades, however, the
growing interest in prodromal or risk states of the illness has
generated renewed interest in the early subclinical expres-
sions and subtle, self-experienced changes in mentation that
had already been observed by Kraepelin [66, 67].
Until the 1980s, scattered and mainly retrospective
reports of the psychotic prodrome prevailed that led to the
formulation of early developmental models of schizophrenia
such as Conrad’s [68] and Docherty’s [69] staging mod-
els, both assuming a unidirectional mandatory pattern of
symptom manifestation. These invariant models, however,
could not be confirmed by retrospective data on the early
course assessed on FEP patients in the Age, Beginning,
Course (ABC) study [16, 70], suggesting that the road to
psychosis might not be a straight one but rather twisted
with stops and returns being possible at any stage [71, 72].
Thus, not knowing where the road is leading when looking at
it prospectively, there is common agreement in prospective
research nowadays not to use the retrospectively defined
term “prodrome” that would indicate that a certain outcome
is inevitable but to emphasise the risk along with the only
more or less probable outcome. To this end, several terms
have been proposed that are often used and considered
interchangeable, even if they originally related to distinct
concepts or assessments. This fact has unfortunately created
Babylonian speech confusion as well as heterogeneity and
variance of findings [73, 74]. In the following, the term “at-
risk mental state” (ARMS) that is not linked to a specific
operationalization or assessment is used when prospectively
relating to a state which may be the prodrome of a FEP.
3.1. Symptomatic Risk Criteria for First-Episode Psychosis.
For the indicated prevention of psychosis in help-seeking
persons already suffering from first signs and symptoms of
the emerging disorder, two approaches were developed in
parallel [75]. Both approaches distinguish between affective
and nonaffective psychotic disorders and nonpsychotic affec-
tive disorders [76, 77]: the basic symptom (BS) approach
targeting the earliest possible specific risk symptoms by
our Cologne group and the ultrahigh risk (UHR) approach
targeting an imminent risk of psychosis with a conversion
within the next 12 months by the Melbourne and New
Haven groups of Patrick McGorry and Thomas McGlashan
(Figure 1).
3.1.1. Basic Symptom Criteria
(1) The Basic Symptom Concept. Relating to early descrip-
tions of prodromal changes by Mayer-Gross [78], the most
thorough early description of subtle early symptoms has
been provided within the framework of the BS concept
[20, 71, 79]. BS are subtle, subjectively experienced subclin-
ical disturbances in drive, stress tolerance, affect, thinking,
speech, attention, body and sensory perception, and motor
action [71]. These subjective symptoms were regarded as the
earliest perceivable signs of the developing psychotic disorder
and its neurobiological correlates—hence the term “basic”
[20]. Although BS vary in their specificity for psychoses
and can occur in nonpsychotic disorders to various degrees
[76, 80, 81], they are recognized nowadays mainly for their
occurrence in initial prodromal states of psychoses including
potential outpost syndromes (i.e., spontaneously remitting
“prodrome-like” phases preceding the prodrome leading to
frank psychosis; Figure 2). Yet, they are not restricted to the
early states but are an integral part of the disorder and can
occur in all states [80–82], that is, within the prodrome of
FEP, within prodromal states of relapse, within residual states,
and even within acute psychotic episodes; consequently, the
assessment of BS can serve several clinical and scientific
purposes (Figure 2).
By definition, BS are not evoked by substance misuse
or somatic illness and differ from what is considered to be
one’s “normal” mental self [71]. Being subjective, they remain
predominately private and apparent only to the affected
person and are rarely directly observable to others but might
be indirectly observed by a patient’s self-initiated coping
strategies in response to BS such as social withdrawal or other
avoidance strategies. It is this emphasis on the subjective, self-
experienced character that distinguishes BS from (i) negative
symptoms in terms of functional deficits observable to others
and (ii) frank psychotic symptoms which are experienced by
the patient as real and normal thoughts and feelings. The
ability to experience BS with insight, however, often attenu-
ates with progressive illness and emerging (attenuated) psy-
chotic symptoms but is commonly restored upon remission
[71].
(2) Assessment Instruments of Basic Symptoms. Two instru-
ments for the binary assessment of presence or absence
of BS were initially developed in concerted action [83]: a
semistructured clinical interview, the Bonn Scale for the
Assessment of Basic Symptoms (BSABS) [84, 85], and a self-
report questionnaire, the Frankfurt Complaint Question-
naire (FCQ) [86]. Nevertheless, the correspondence between
BSABS and FCQ subscales was poor, indicating that the
mode of assessment is a crucial factor in the evaluation of BS
[67, 87].
Advances in Psychiatry 5
ProdromePremorbidphase Psychosis
Postpsychotic
states
Psychosis threshold
Threshold for basic
symptoms incl. in
COPER and COGDIS
Threshold for unspecific
basic symptoms
∙ Detailed description
of trait markers (“7”),
e.g., in genetic high
risk studies
∙ Improving patient’s encounters
with and motivations for
treatment by relating
therapeutic strategies to the
self-recognized mental changes
∙ Supporting patients and their
families in acquiring a deeper
understanding of the expected
vicissitudes of their illness, an
important step in overcoming
some of the intractability and
terror often associated with
the disorder
∙ Early detection of at-risk mental states
∙ Initiation of benign psychotherapeutic
early interventions
∙ Reduction of the duration of untreated
illness whose longer duration was
correlated with a reduced improvement
in psychosocial functioning after 12months
∙ Supporting insight into the pathogenesis of
psychoses
Thorough descriptions of
(1) the degree of remission
beyond positive and
negative symptoms,
(2) chronic states and
symptoms underlying
persistent negative
symptoms
(3) early detection of relapse
∙ Inclusion into awareness and information campaigns of psychosis
to promote self-initiated help-seeking when insight is still
maintained and psychosocial functioning not yet as severely impaired
as in ultrahigh risk states
(1) (2) (3) titrating adequate
combinations of pharmacological
psychological,
and rehabilitative interventions
(3)
(2)
(1)
“Outpost syndrome”
Figure 2: Range of possible applications of basic symptom assessment (according to [71, 91]). Annotation: (“7”): SPI-A/SPI-CY rating for
basic symptom-like phenomena that are reported as having always been present in the current frequency in a trait-like manner.
Based on the BSABS, we developed an instrument for the
quantitative clinical assessment of BS [67, 88], that is, the
Schizophrenia Proneness Instrument, in two versions, that is,
an Adult (SPI-A; [89]) and a Child and Youth version (SPI-
CY; [90, 91]). With regard to the development of the SPI-A,
the six BS dimensions in adult samples exhibited a robust
structure across samples in different stages of the illness [88].
This structure even remained largely unchanged when BS
assessment turned from the binary assessment of presence
in the BSABS to an ordinal assessment of frequency-guided
severity in the SPI-A. Yet, the structure could not be replicated
in a sample of patients with nonpsychotic depressive disor-
ders. Thus, it was concluded that these dimensions might be
inherent and unique to schizophrenia and other psychoses
and, therefore, can serve as valid and reliable subscales of an
instrument for the assessment of BS [88]. Building on this,
the final version of the SPI-A was developed after validation
on a second prospectively assessed truly prodromal sample
[67, 89].The SPI-A has shown good interrater reliability with
an increase of the overall concordance rate with an expert
rating from 60% to 89% across five training sessions [67, 89].
Though very consistent in adult samples, the six-
dimensional structure of BS was absent in an EOP sample
[62, 67]. Rather, a four-dimensional structure was revealed
that formed the basis for the subscales of the SPI-CY—thus
far the only early detection instrument especially designed for
use in children and adolescents aged 8 and older [62, 67, 91].
A striking structural difference between the SPI-A and SPI-
CY was that adynamic BS (e.g., lack of energy, motiva-
tion, drive, or (positive) feelings including sudden depres-
sive mood, decreased stress tolerance, increased emotional
responsiveness, and general cognitive impediments such as
concentration, memory, and attention problems or reports of
a “blank mind”) appeared to play a central role in children
and adolescents; this central position was held in adults by
mainly cognitive BS, including those included in BS risk
criteria described below [67]. The discriminative validity of
the SPI-CY was preliminarily confirmed on three groups of
children and adolescents: risk patients meeting UHR and/or
BS criteria (AtRisk), clinical inpatient controls not suspected
to be at risk for developing psychosis (ClinS), and children
and adolescents from the general population (GPS) [92]. As
expected, the groups differed significantly on all four SPI-
CY subscales with the AtRisk sample scoring highest and
the GPS lowest and at least moderate between-group effects
that were largest for the subscale “Adynamia.” However, these
results require validation in a larger sample, and longitudi-
nal studies should examine the psychosis-predictive ability
of the subscales in different young age groups, especially
the role of Adynamia. In cooperation with the Cologne
and Zurich University Hospitals for Child and Adolescent
Psychiatry, we are currently addressing these questions in
a prospective study, the Binational Evaluation of At-Risk
Symptoms in Children and Adolescents (BEARS-Kid) study,
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Table 1: At-risk criterion cognitive-perceptive basic symptoms (COPER) [89, 97].
Presence of at least any one of the following ten basic symptoms with at least weekly occurrence (i.e., a SPI-A/SPI-CY score of ≥3)
within the last three months and first occurrence at least 12 months ago (irrespective of frequency and persistence during this time):
(i) thought interference (C2)a
(ii) thought perseveration (O1)
(iii) thought pressure (D3)
(iv) thought blockages (C3)
(v) disturbance of receptive speech (C4)
(vi) decreased ability to discriminate between ideas and perception, fantasy and true memories (O2)
(vii) unstable ideas of reference (D4)
(viii) derealisation (O8)
(ix) visual perception disturbances, excl. blurred vision and hypersensitivity to light (D5, F2, F3, and O4)
(x) acoustic perception disturbances, excl. hypersensitivity to sounds (F5, O5)
aItem numbers refer to the SPI-A.
Table 2: High risk criterion cognitive disturbances (COGDIS) [89, 97].
Presence of at least any two of the following nine basic symptoms with at least weekly occurrence (i.e., a SPI-A/SPI-CY score of ≥3)
within the last three months:
(i) inability to divide attention (B1)a
(ii) thought interference (C2)
(iii) thought pressure (D3)
(iv) thought blockages (C3)
(v) disturbance of receptive speech (C4)
(vi) disturbance of expressive speech (C5)
(vii) unstable ideas of reference (D4)
(viii) disturbances of abstract thinking (O3)
(ix) captivation of attention by details of the visual field (O7)
aItem numbers refer to the SPI-A.
which is funded by a common grant of the Swiss National
Science Foundation and the German Research Foundation
and examines four groups of altogether 800 children and
adolescents (e.g., patients meeting ARMS criteria, inpatients
with no clinical suspicion of an ARMS, patients with an EOP,
and children and adolescents of the general population) for
three years [http://p3.snf.ch/project-144100].
(3) The Basic Symptom Criteria for an At-Risk Mental State.
The Cologne Early Recognition (CER) study [67, 85, 93–
95] was the first ever long-term naturalistic prospective early
detection studywith amean follow-up period of 9.6 years and
investigated the psychosis-predictive accuracy of BS assessed
with the BSABS in 160 adult patients clinically suspected
to be at risk for schizophrenia. Based on different types of
analyses, two BS criteria that share some of the included
BS were developed from its data [67, 85, 93–95]: “cognitive-
perceptive basic symptoms” (COPER; Table 1) and “cognitive
disturbances” (COGDIS; Table 2).
Compared to COPER, COGDIS seem to have a higher
specificity, that is, are associated with higher conversion rates
(Table 3), yet this might be at the cost of sensitivity, that is,
related to missing more patients who are in fact about to
develop a FEP [67]. In other words, COGDIS performed
better in ruling in conversion to psychosis (moderate positive
diagnostic likelihood ratio of 3.9), while COPER performed
better in ruling it out (moderate negative diagnostic like-
lihood ratio of 0.23) [93, 96]. Thus, in terms of a clinical
staging, these BS criteria were thought to be possibly able
to serve different clinical purposes in adult samples, that
is, broad risk detection and symptom monitoring based on
COPER versus risk detection with the intention to initiate
specific psychosis-preventive treatment by COGDIS [93].
Subsequent studies by our group [97–100] and others
[101, 102] confirmed the psychosis-predictive ability of both
COPER and COGDIS, although conversion rates were some-
what lower at comparable follow-ups (Table 3). This decline
might be caused by conservatively accounting for drop-outs
as nonconverters [97–100], exclusion of symptomatic UHR
criteria [98], age-related peculiarities [102], or other factors
related to changes in referral and treatment practice that
had been discussed in relation to the much more severe
decline in conversion rates observed inUHR samples [103]. In
addition, differences in conversion rates might also be related
to differences in the BS composition of samples. Analyses of
converters of the CER study with different duration of the
prodrome defined as short (<1 year), medium (1–6 years),
and long (>6 years) revealed group differences particularly in
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Table 3: Conversion rates for COPER and COGDIS in (sub)samples not systematically treated for psychosis-risk.
Study BS criterion,𝑁 (𝑁 criterion positive), predominant agegroup, 𝑛 (%) lost-to-last-follow-up of total sample
Conversion rate at month
12 18 24 36 >36
[93, 95] COPER, 160 (106), adults, n.a.COGDIS, 160 (67), adults, n.a.
20%
24%
37%
46%
50%
61%
65%c
79%c
[97] COPER, 146 (146), adults, 60 (41%)
b
COGDIS, 146 (124), adults, 60 (41%)b
25%
25%
33%
33%
[98]a COPER, 128 (64), adults, 23 (36%)b 17% 20%
[99, 114] COGDIS, 245 (171), adults, 62 (25%)b 14% 19%
[101] COGDIS, 73 (48), adults, n.a. 25%
[102] COGDIS, 72 (39), adolescents, 15 (21%)b 18%
[100] COGDIS, 246 (158), adults, 56 (23%)b 23% 34% 40% 42%d
aSupportive counselling control condition only; conversion rate includes conversion to a late state, that is, development of APS or BLIPS.
bThose lost-to-follow-up were conservatively regarded as nonconverters, symptomatic UHR criteria excluded.
cMinimum of 60 months, maximum of 359 months.
dMonths 36 to 48.
n.a.: not applicable; only patients with complete follow-up data were included.
cognitive BS constellations that could be interpreted in terms
of differences in underlying deficits in information processes,
that is, in bottom-up, top-down, or central integrative pro-
cesses [104]. Because of the current lack of sufficiently long
follow-up data, these etiological considerations still await
confirmation in independent samples as well as examination
in neurocognitive studies.
3.1.2. Combining Basic Symptom and Ultrahigh Risk Criteria.
Initially developed independently of each other, BS and UHR
criteria (Table 4) frequently cooccur and are increasingly
applied together—first within our Cologne Early Recognition
and Intervention Centre (FETZ), Europe’s pioneer early
detection service for adults in an ARMS [97, 100, 105, 106].
A combined approach was adopted and first operationalized
within the German Research Network on Schizophrenia
(GRNS) [107] as a clinical staging model [108, 109] distin-
guishing an early from a late risk state [110] (Figure 1): an
early risk state was alternatively defined by COPER and the
UHR state-trait criterion, and a late risk statewas alternatively
defined by attenuated psychotic symptoms (APS) and brief
limited intermittent psychotic symptoms (BLIPS).
The sequence by which symptoms progress according
to the clinical staging model for ARMS [107–111]—from
unspecificmental problems via first BS of COPER and second
APS to psychotic symptoms (Figure 1)—was supported on
retrospective data of FEP inpatients [17]. Furthermore, both
approaches exhibited good sensitivity in this sample: 79%
of the sample reported COPER and 71% APS, whereby 63%
reported both APS and COPER [17]. A rather large but not
complete overlap between BS and UHR criteria was also
apparent in other ARMS studies [97, 99–102, 105].
Moreover, the highest 18-month and 48-month conver-
sion rates showed for the combination of COGDIS and
UHR criteria (mainly APS) compared to either COGDIS or
UHR criteria alone [67, 99, 100]. For example, within a 48-
month follow-up [100], COPER and UHR criteria exclusive
of each other revealed hazard rates of 0.23 and 0.28. In line
with the GRNS staging model, in the “only UHR” group,
conversions occurred between months 1 and 8, while in the
“only COGDIS” group, conversions occurred after month
5 but continued throughout the follow-up thereafter. The
combined group “COGDIS plus UHR” showed conversions
throughout the 48 months at a hazard rate of 0.66. Notably,
irrespective of each other both COGDIS andUHR showed an
equal but lower hazard rate of 0.56 [100].
These findings support the merits of considering both
COGDIS and UHR criteria in the early detection of persons
who are at high clinical risk of developing a FEP; the
combination with COPER has not yet been explicitly studied.
Applying both sets of criteria improves the sensitivity of risk
detection and the individual risk estimation; it may thereby
support the development of stage-targeted interventions.
Moreover, since the combination of COGDIS and UHR cri-
teria enables the identification of considerably more homo-
geneous ARMS samples, it should support both preventive
and basic research [100]. However, for the still considerable
number of false-positive predictions, potential additional
predictors enhancing the overall predictive accuracy—ideally
without simultaneously reducing sensitivity—continue to be
studied at all levels.
3.2. Searching for Additional Predictors to Enhance Predictive
Accuracy. Across early detection studies, the addition of pre-
dictors frequently raised specificity at the cost of sensitivity,
that is, frequently leading to a higher rate of exclusion of
truly prodromal patients from preventive measures [112]. A
possible solution to this dilemma, well-established in somatic
medicine, is risk stratification [112, 113]. Risk stratification
was first introduced in psychiatric prevention researchwithin
the European Prediction of Psychosis Study (EPOS) [99, 114],
which used COGDIS and UHR criteria as assessed with the
Structured Interview for Psychosis-Risk Syndromes (SIPS;
[115]) to detect mainly adult ARMS patients. Examining
additional psychopathological predictors, four risk classes for
the 18-month conversion riskwere identified based on a prog-
nostic index calculated fromAPS severity, sleep disturbances,
schizotypal personality disorder, and functioning and edu-
cational level [28]. Notably, the highest risk class contained
a much higher percentage (83%) of persons reporting both
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Table 4: Ultrahigh risk criteria according to the Structured Interview for Psychosis-Risk Syndromes (SIPS) [115].
“Brief limited intermittent psychotic symptom” (BLIPS) syndrome
(i) At least any 1 of the following SIPS P-items scored 6 “severe and psychotic”:
(a) P1 unusual thought content/delusional ideasa
(b) P2 suspiciousness/persecutory ideas
(c) P3 grandiose ideas
(d) P4 perceptual abnormalities/hallucinations
(e) P5 disorganized communication
(ii) First appearance in the past three months
(iii) Present for at least several minutes per day at a frequency of at least once per month but less than 7 days
“Attenuated psychotic symptom” (APS) syndromeb
(i) At least any 1 of the following SIPS P-items scored 3 “moderate” to 5 “severe but not psychotic”:
(a) P1 unusual thought content/delusional ideas
(b) P2 suspiciousness/persecutory ideas
(c) P3 grandiose ideas
(d) P4 perceptual abnormalities/hallucinations
(e) P5 disorganized communication
(ii) First appearance within the past year or current rating one or more scale points higher compared to 12 months ago
(iii) Symptoms have occurred at an average frequency of at least once per week in the past month
“Genetic risk and functional deterioration” (GRFD) syndrome
(1) Patient meets criteria for schizotypal personality disorder according to SIPS
(2) Patient has 1st degree relative with a psychotic disorder
(3) Patient has experienced at least 30% drop in the global assessment of functioning (GAF) score over the last month compared to 12
months ago
[1 and 3] or [2 and 3] or all are met
aItem numbers refer to the SIPS.
bIn the definition of the Attenuated Psychosis Syndrome ofDSM-5, requirements (i) to (iii) are complimented a fourth requirement; that is, significant disability
or distress is caused by APS.
COGDIS and UHR criteria than all other risk classes (55–
57%).
Other possible psychopathological predictors in adult
samples were bipolar, somatoform, and unipolar depressive
disorders at baseline, while anxiety disorders at baseline
were negatively associated with conversion [116], the Strauss
and Carpenter Prognostic Scale items assessing quality of
useful work and social relations, positive symptoms and
subjective distress [117], presence of ideas of reference and
lack of close interpersonal relations as assessed with the
Schizotypal Personality Questionnaire [118], and schizoid
personality traits but neither schizotypal personality traits
[119] nor dimensions of normal personality [120]. Together,
these results point to an important role of functional deficits,
especially in social contexts, high emotional responsiveness,
and severity and persistence of APS in the development of
psychosis in adult ARMS patients.
Another line of research on predictors has focussed on
deficits in information processing that are common in FEP
and have also been observed in ARMS patients, albeit to a
lesser degree [121–124]. Objectively assessed neurocognitive
deficits were widely independent of the subjectively reported
cognitive disturbances included in COPER and COGDIS,
thus offering the possibility to explain additional variance
between ARMS patients who do or do not convert to psy-
chosis [125]. Conversion was repeatedly related to processing
speed deficits and lower premorbid verbal IQ, while results
on the additional value of verbal memory deficits were
conflicting [126, 127].
Similar to neurocognitive deficits, also electrophysiolog-
ical abnormalities have been reported in both psychosis
and adult ARMS patients with only slight differences [128,
129]. Abnormalities in mismatch negativity and quantitative
EEG parameters have been associated with conversion [130,
131]. Another line of research, which evaluated biochemical
abnormalities as potentially valuable predictors, found that
anandamidergic upregulation might be a protector against
conversion in ARMS patients [132, 133].
As many of these results have been generated inde-
pendently of one another, future research should use large
samples to ensure a sufficient number of converters so
that simultaneous analyses of potential predictors and their
interactions can be performed. In this way, nonredundant
predictors that are most useful for a risk stratification of
ARMS patients can be identified. Furthermore, while some
of the potential predictors such as functional deficits, greater
symptom severity, abnormalities in mismatch negativity, and
processing speed deficits have already been replicated by
other work groups (see [75] for overview), other results such
as the protective role of an anandamidergic upregulation are
still in need for replication in independent samples. And last
but not least, all potential predictors still need to be studied
for developmental differences in children and adolescent
samples.
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3.3. Clinical Significance of the At-Risk Mental State. ARMS
patients, however, not only are at risk for future psychosis but
also are already suffering from a wide range of mental prob-
lems. In addition to the neurocognitive and electrophysiolog-
ical abnormalities described above, they exhibit poor premor-
bid adjustment and deficits in psychosocial functioning and
subjective quality of life that tend to worsen from the early to
the late risk state [134–137]. Notably, a considerable number
experience improvement in psychosocial outcome following
the detection of an ARMS [138]. Furthermore, many ARMS
patients suffer from other nonpsychotic mental disorders,
frequently depression and anxiety [105, 116, 139]. Thus it was
not surprising that the pattern of coping, self-efficacy, and
control beliefs of ARMS patients closely resembled that of
depressive patients in its frequent lack of positive coping
strategies, low self-efficacy, and a fatalistic externalizing bias
[140].
As we and others [75, 141] have shown that help-
seeking ARMS samples are clinically significant, in 2008,
we raised the question of whether current early detection
approaches really target the “prodrome” of psychosis or rather
a psychosis-spectrum disorder with a high risk for psychotic
symptoms as one of the key questions in early detection
research [142].This issue becamewidely discussed a year later
with the suggestion of including a psychosis-risk syndrome
based on APS in DSM-5 [143]. In line with our rationale
for a self-contained disorder [112, 144], this proposal was
later revised to an APS-based self-contained disorder, the
Attenuated Psychosis Syndrome [145]. As such, it was finally
included in Section III of DSM-5 as a condition for future
studies [146, 147]. Besides questions related to reliability, this
decision was made for the unknown prevalence and clinical
significance of such a syndrome outside help-seeking samples
in the community [147].
3.4. Risk Criteria and Symptoms in the Community. The
clinical significance of risk symptoms, in particular APS,
outside help-seeking samples in the community had been
called into question by the high prevalence rates reported for
subclinical psychotic symptoms or psychotic-like experiences
(PLEs) in the community. PLEs, however, have commonly
been assessed by self-report questionnaires or layperson fully
structured interviews and thus provide no valid measure of
clinician-assessed APS or psychotic symptoms but signifi-
cantly overestimate their prevalence [148]. Thus it was con-
cluded that dedicated studies are warranted, in which APS—
and other risk criteria—are assessed in a way that equates to
their clinical evaluation. Supported by a grant from the Swiss
National Science Foundation and following confirmation of
the reliability of telephone assessments of risk symptoms
[149], we started such a study, the Bern Epidemiological At-
Risk (BEAR) study, in 2011 (http://p3.snf.ch/project-135381).
Both an interim analysis of the BEAR study and results from
a proof-of-concept study [150, 151]confirmed our expectation
that APS criteria and Attenuated Psychosis Syndrome are
infrequent: theyweremet by less than 0.5% of the 1229mainly
adult interviewees that entered the interim analyses of the
BEAR study. At symptom level, APS were reported by 13% of
the sample and, indicating a clinical significance of APS in the
community, were associated with functional impairments,
current mental disorders, and help-seeking although they
were not a reason for help-seeking [150]. Future analyses
of the full sample of 16–40-year-olds after conclusion of
the BEAR study in July 2014 will show if these results are
maintained in a larger sample, while comparison with data
with the 8–17-year-old community sample of the BEARS-Kid
study will help to identify age-related peculiarities that were
suggested by Kelleher et al. in their adolescent samples [152].
Furthermore, the aspired follow-up of the BEAR sample will
reveal the course and impact of risk symptoms and criteria
over time.
As regards BS criteria, COPER and COGDIS and their
included BS were as equally rare as APS in the small
proof-of-concept study [151], though further confirmation is
needed from the larger sample queried in the BEAR study
[150]. Furthermore, irrespective of their frequency, any one
COPER-BS and any two COGDIS-BS were reported by only
8% and 3% of adolescents in the general population [153].
4. Conclusion and Outlook
For the lack of a significant breakthrough in the treatment of
psychotic disorders after the onset of the first episode and due
to the negative impact of the frequent and often years-long
delays in the initiation of an adequate treatment on outcome,
hopes are that indicated prevention of psychotic disorders
in persons with first signs of the developing disorder will
provide such a breakthrough [61, 75, 109, 154, 155]. To this
end, an accurate and reliable early detection, that is, the
development of exact, broadly applicable, and economic risk
criteria, is a prerequisite.
Thus, the accuracy of prediction along with the safety
of treatment has been in the main focus of critics and
of, sometimes heated, ethical debates [156]. While further
research is certainly needed, it is confronted with a dilemma
of preventive research: with the growing awareness of the
need for treatment in help-seeking ARMS patients and,
consequently, its provision, the observation of the long-term
natural course of potential risk symptoms that is neces-
sary to develop accurate prediction models is increasingly
impossible in clinical samples.The consideration of treatment
effects as confounders in prediction analyses however not
only raises the need for ever larger samples but also is
hindered by the lack of knowledge about their long-term
effectiveness [157, 158]. Yet a recent review reported a rather
robust overall risk reduction across ten pharmacological
and psychological early intervention studies at 12 months
of 54% with a number-needed-to-treat of nine [159]. For
this reason, longitudinal epidemiological studies that reliably
and validly assess clinical risk criteria and symptoms in the
general population become increasingly important, such as
our BEAR study, the first epidemiological study on a large
random representative sample of a broad age range and with
a sufficient response rate of nearly 70% [150]. Such studies in
unselected community samples might also help to alleviate
fears about pathologising “normal” experiences that have
been raised by reports on frequent and mostly benign PLEs
in the community [147]. However, the benign PLEsmeasured
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by self-report in community samples may not be a valid
measure of clinician-assessed symptoms [148]. Furthermore,
community studies should increase knowledge about help-
seeking to detect starting-points for increasing early help-
seeking, because, at the currently low rate of only about
30% of FEP patients seeking help prior to the onset of frank
psychotic symptoms [13, 14], a significant reduction of the
incidence of psychosis—the ultimate target of prevention—
will not be in sight. Another question that epidemiological
research will help to address is whether to continue to regard
current criteria as risk criteria with the main outcome being
progression to psychosis and the main treatment target being
its prevention or to rather perceive them as a self-contained
syndrome in that remission, persistence, and progression,
for example, to psychosis, are equally possible outcomes and
in that the main treatment targets are current symptoms
[112, 144]. In both cases, however, the search for additional
predictors of psychosis will continue.
Today, this search mainly relies on group differences that
greatly depend on the studied sample and, consequently,
are hard to transfer into clinical practice, that is, on the
risk estimation of an individual patient [127, 140]. Thus,
where available such as for neurocognitive or psychological
tests, deficits should be defined according to independent
test norms, and risk stratification approaches should be
presented in a way acceptable to clinicians, that is, not as
scores of a complex regression equation but as clear decision
rules relying on certain patterns of aberrations [127, 160].
Such a presentation would also facilitate the validation of
prediction rules in other samples. The use of norms that
are generally already gender- and age-adjusted might also
help to avoid heterogeneity in data related to gender and,
more importantly, age effects that have just been started to be
addressed in this line of research [62–65, 67, 92, 161, 162], for
example, by our multicentre BEARS-Kid study.
Age effects and needs of young age will also have to
be considered in early intervention research in both ARMS
and FEP patients, in particular with regard to more benign
psychotherapeutic interventions [161]. Early interventions in
an ARMS that have so far mainly focussed on risk symptoms
and comorbidities [155, 157] might thereby broaden their
focus to enhancing general resilience factors such as adequate
coping strategies, metacognitive beliefs, or sleep [140, 163].
In summary, while exciting process has already been
made in the field of early psychosis—both ARMS and FEP—
much remains to be done. And while psychosis research
has traditionally been mainly carried out in general psy-
chiatry and adult samples, research on early psychosis and,
consequently, rather young patients calls for a stronger
involvement of child and adolescent psychiatry and recon-
sideration of the often strict age-related separation of fields
of responsibility of the two professions. A successful exam-
ple is the FETZ Bern (http://www.fetz.gef.be.ch/fetz gef/de/
index/navi/index.html), an early detection and intervention
service that serves patients between the ages of 8 and 40—
and, at this, the worldwide largest age range—and is run
as a cooperation of the Bern University Hospitals for Child
and Adolescent Psychiatry, and Psychiatry, and the Soteria
Bern.
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